Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

5387 - Long-term tolerability of olaparib tablets as maintenance therapy for platinum-sensitive relapsed ovarian cancer (PSR OC): Phase III SOLO2 trial

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Topics

Cytotoxic Therapy

Tumour Site

Ovarian Cancer

Presenters

JACOB KORACH

Citation

Annals of Oncology (2018) 29 (suppl_8): viii332-viii358. 10.1093/annonc/mdy285

Authors

J. KORACH1, G. Freyer2, S. Banerjee3, R. Asher4, J. Cosin5, A.M. Oza6, A.M.M. Poveda Velasco7, M. Di Napoli8, C. Scott9, M. Lapresa10, F. Heitz11, K. Takehara12, G.S. Sonke13, S. Tjulandin14, J. Kim15, R. Hegg16, I.B. Vergote17, S. Turner18, E. Pujade-Lauraine19

Author affiliations

  • 1 Gynecologic Oncology, Chaim Sheba Medical Center, Tel Aviv University, 52621 - Tel Aviv/IL
  • 2 Medical Oncology, Lyon University Hospital Cancer Institute, Lyon/FR
  • 3 Gynaecology Unit, The Royal Marsden NHS Foundation Trust, SW3 6JJ - London/GB
  • 4 Nhmrc Clinical Trials Centre, University of Sydney, Camperdown/AU
  • 5 Gynecologic Oncology, Hartford Healthcare Cancer Institute, New Britain/US
  • 6 Medical Oncology And Hematology, Princess Margaret Cancer Center, M5G 2M9 - Toronto/CA
  • 7 Medical Oncology, Fundación Instituto Valenciano de Oncología, 46009 - Valencia/ES
  • 8 Irccs Fondazione Pascale, Istituto Nazionale Tumori, 80131 - Naples/IT
  • 9 Walter And Eliza Hall Institute Of Medical Research, Peter MacCallum Cancer Centre, Melbourne/AU
  • 10 Division Of Gynaecology, Istituto Europeo di Oncologia, Milan/IT
  • 11 Gynaecological Oncology, Kliniken Essen-Mitte, Essen/DE
  • 12 Gynecologic Oncology, National Hospital Organization Shikoku Cancer Center, 791-0280 - Matsuyama/JP
  • 13 Department Of Medical Oncology, The Netherlands Cancer Institute, 1066 CX - Amsterdam/NL
  • 14 Department Of Clinical Pharmacology And Chemotherapy, NN Blokhin Russian Cancer Research Center, Moscow/RU
  • 15 Gynecologic Oncology, Seoul National University College of Medicine, Seoul/KR
  • 16 Oncology Research Center, Pérola Byington Hospital, 04524-003 - São Paulo/BR
  • 17 Gynecology, University of Leuven, Leuven Cancer Institute, 3000 - Leuven/BE
  • 18 Global Medicines Development, AstraZeneca, CB2 1PG - Cambridge/GB
  • 19 Medical Oncology, Université Paris Descartes, AP-HP, Paris/FR
More

Resources

Abstract 5387

Background

The PARP inhibitor olaparib (Lynparza®) has shown significant efficacy as maintenance therapy for patients (pts) with PSR OC, especially pts with BRCA mutations, as capsules (Ledermann et al Lancet Oncol 2014) and tablets (Pujade-Lauraine et al Lancet Oncol 2017). Olaparib capsules have shown long-term benefit, with pts staying on treatment for ≥5 years (yrs; Gourley et al ASCO 2017). We analysed the long-term tolerability of olaparib tablets in the SOLO2 trial (ENGOT-Ov21; NCT01874353).

Methods

In SOLO2, pts with BRCA-mutated PSR OC in response to platinum received maintenance olaparib tablets (300 mg bid) or placebo until disease progression. Adverse events (AEs) were graded by CTCAE v4.0.

Results

At the primary data cut-off (DCO; 19 Sep 2016), of 195 pts treated with olaparib, 62 (32%) had received olaparib for ≥1–<2 yrs (Group 1) and 59 (30%) for ≥2 yrs (Group 2), vs 12/99 (12%) and 9/99 (9%), respectively, who received placebo. Most AEs that began after ≥1 yr (Group 1) or ≥ 2 yrs (Group 2) were grade 1–2, with few serious AEs (Table). The most common AEs with onset during the second yr of olaparib treatment were anaemia (19%), nausea (18%), and vomiting (15%). The most common AEs with onset after ≥2 yrs were diarrhoea (8%), abdominal pain (5%), and upper abdominal pain (5%). Four pts in Group 1 discontinued olaparib because of AEs (acute myeloid leukaemia, decreased neutrophil count, muscular weakness, disturbance in attention and depression; all n = 1) vs no pts in Group 2.Table: 952P

Long-term AE data for olaparib tablets as maintenance therapy

Group 1 (n = 62)Group 2 (n = 59)
AEs with onset reported during the second yr (≥1–<2 yrs) of olaparib treatmentAEs with onset reported after ≥2 yrs of olaparib treatment
AE (any grade), n (%)54 (87)23 (39)
AE (grade ≥3), n (%)11 (18)1 (2)
Serious AE, n (%)7 (11)1 (2)
Dose interruption caused by AE, n (%)14 (23)4 (7)
Dose reduction caused by AE, n (%)4 (6)0
Treatment discontinuation caused by AE, n (%)4 (6)0

Conclusions

AEs reported during long-term olaparib maintenance therapy were mostly low grade, non-serious and associated with a low rate of treatment discontinuation. Common AEs were consistent with the known safety profile. Olaparib tablets are suitable for long-term maintenance therapy for PSR OC pts, without cumulative toxicity and with few late-onset AEs.

Clinical trial identification

NCT01874353, January 2017.

Legal entity responsible for the study

AstraZeneca.

Funding

AstraZeneca.

Editorial Acknowledgement

Editorial assistance was provided by Rachel Patel, Mudskipper Business Limited, funded by AstraZeneca.

Disclosure

J. Korach: Advisory board member: AstraZeneca Israel. G. Freyer: Board and speaker fees: AstraZeneca, Pfizer, Lilly, Novartis, Biogaran, Clovis, Amgen; Speaker fees: Roche; Research funding: AstraZeneca, BMS, Amgen; Consultant honoraria: Amgen. S. Banerjee: Honoraria: AstraZeneca, Tesaro, Clovis, PharmaMar, and Gamamabs; Research funding to institution: AstraZeneca. J. Cosin: Consultant for Medtronic. A.M. Oza: Steering committees (non-compensated) for trials: AstraZeneca, Clovis, Tesaro; Honoraria: Intas Pharma. A.M. Poveda: Advisor: AstraZeneca, Roche, Tesaro, Clovis, PharmaMar. C. Scott: Personal fees and non-financial support: AstraZeneca; Grants, personal fees, non-financial support, and others: Clovis Oncology, Roche; Others: Eisai Australia, Beigene. M. Lapresa: Fees: AstraZeneca, PharmaMar. G.S. Sonke: Institutional research support: AstraZeneca, Merck, Novartis, Roche. S. Tjulandin: Honoraria: AstraZeneca, Pfizer, Eli Lilly, MSD, Hoffmann La Roche. I.B. Vergote: Advisory board fees: Roche, Genmab, Advaxis, Morphotek, Hoffmann La Roche, Cerulean Pharma, Novocure, AstraZeneca, Mateon Therapeutics, Immunogen, Eli Lilly Benelux, Amgen, Theradex Europe, Pfizer, Debiopharma International, Vifor Pharma, Novartis, MSD, Janssen-Cilag, Bayer, Clovis Oncology, Takeda, PharmaMar, Oncoinvent; Research grants: Amgen, Roche; Accommodation and travel expenses: Tesaro, Clovis Oncology, Takeda, PharmaMar, Roche, Genmab, Oncoinvent; Institutional research grants: Morphotek. S. Turner: Employee of AstraZeneca and owns stock. E. Pujade-Lauraine: Honoraria, advisory board member: AstraZeneca, Roche, Tesaro, Clovis, Pfizer. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.